BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 16434454)

  • 1. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.
    Pagán YL; Srouji SS; Jimenez Y; Emerson A; Gill S; Hall JE
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1309-16. PubMed ID: 16434454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
    Arroyo A; Laughlin GA; Morales AJ; Yen SS
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome.
    Srouji SS; Pagán YL; D'Amato F; Dabela A; Jimenez Y; Supko JG; Hall JE
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1347-52. PubMed ID: 17264175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome.
    Patel K; Coffler MS; Dahan MH; Malcom PJ; Deutsch R; Chang RJ
    Clin Endocrinol (Oxf); 2004 Jan; 60(1):67-74. PubMed ID: 14678290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics.
    Hayes FJ; Taylor AE; Martin KA; Hall JE
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2343-9. PubMed ID: 9661606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.
    Taylor AE; McCourt B; Martin KA; Anderson EJ; Adams JM; Schoenfeld D; Hall JE
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2248-56. PubMed ID: 9215302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Pastor CL; Griffin-Korf ML; Aloi JA; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 1998 Feb; 83(2):582-90. PubMed ID: 9467578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS).
    Lewandowski KC; Cajdler-Łuba A; Salata I; Bieńkiewicz M; Lewiński A
    Endokrynol Pol; 2011; 62(2):120-8. PubMed ID: 21528473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
    Holte J; Bergh T; Gennarelli G; Wide L
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback.
    Hayes FJ; Seminara SB; Decruz S; Boepple PA; Crowley WF
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3027-35. PubMed ID: 10999781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome.
    McCartney CR; Eagleson CA; Marshall JC
    Semin Reprod Med; 2002 Nov; 20(4):317-26. PubMed ID: 12536355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness.
    van den Berghe G; Weekers F; Baxter RC; Wouters P; Iranmanesh A; Bouillon R; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3217-26. PubMed ID: 11443192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women.
    Couzinet B; Young J; Kujas M; Meduri G; Brailly S; Thomas JL; Chanson P; Schaison G
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4191-6. PubMed ID: 10566671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
    Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
    Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.